Home / Deep Research / Lichen Simplex Chronicus and Prurigo

Lichen Simplex Chronicus and Prurigo

Pathophysiology Overview (Itch-Scratch Cycle and Neuroimmune Dysregulation)

2026-02-01
OpenAI Model: o3-deep-research-2025-06-26 138 citations

Pathophysiology Overview (Itch-Scratch Cycle and Neuroimmune Dysregulation)

Lichen simplex chronicus (LSC) and prurigo nodularis (a form of chronic prurigo) are chronic pruritic skin disorders driven by a self-perpetuating itch–scratch cycle and neuroimmune dysregulation (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Persistent itch sensations provoke repetitive scratching or rubbing of the affected skin, leading to lichenification (thickening and hyperpigmentation of skin in LSC) or pruritic nodules (in prurigo) (pmc.ncbi.nlm.nih.gov) (www.ncbi.nlm.nih.gov). This mechanical trauma disrupts the epidermal barrier and induces local inflammation, which in turn releases pruritogenic mediators that further intensify itch – a vicious cycle maintaining chronic disease (pmc.ncbi.nlm.nih.gov) (www.ncbi.nlm.nih.gov). Psychological stress and neurogenic factors often initiate or exacerbate this cycle; patients with anxiety, depression, or obsessive tendencies are prone to scratching, highlighting a psychodermatologic component (www.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Indeed, stress-related dysregulation of the hypothalamic–pituitary–adrenal (HPA) axis and reduced neurotrophic factors (e.g. brain-derived neurotrophic factor, nerve growth factor) may lower itch thresholds and impair neuronal resilience (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). The result is chronic localized dermatitis with prominent neuroimmune activation, even if the initial trigger (such as an eczema patch, bug bite, or neuropathic itch) has resolved (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). In summary, LSC and prurigo are neuroinflammatory dermatoses in which persistent itch leads to self-trauma, causing skin barrier damage and an exaggerated immune response, which loops back to cause more itch (the “itch–scratch cycle”) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This core pathophysiology underlies the clinical hallmarks of these conditions: chronic pruritus, thickened scaly skin or nodules, and often secondary pigmentation changes and excoriations.

Type 2 Immunity and Key Cytokine Pathways

A defining feature of LSC and chronic prurigo is a type 2 helper T-cell (Th2) skewed inflammation, analogous to atopic dermatitis. Lesional skin shows high levels of Th2 cytokines – notably interleukin-4 (IL-4) and interleukin-13 (IL-13) – which drive allergic inflammation and itch (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). “The IL-4/IL-13/IL-4R axis promotes the differentiation of type 2 helper T cells (Th2), which mediate the pro-allergic adaptive immune response.”* (pmc.ncbi.nlm.nih.gov). Activation of the IL-4 receptor (IL4Rα, HGNC:6025) on immune cells triggers the JAK–STAT signaling cascade (primarily JAK1/JAK3 and STAT6), leading to Th2 gene transcription and IgE production (pmc.ncbi.nlm.nih.gov). This pathway is so central that a monoclonal antibody against IL-4Rα (dupilumab) markedly improves prurigo nodularis by blocking IL-4/13 signaling (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov), confirming the pathogenic role of Th2 cytokines. Downstream, IL-4 and IL-13 also induce fibroblast proliferation and fibrosis – they upregulate pro-fibrotic genes like collagen and TGF-β in the dermis, contributing to the thickened, fibrotic nodules** seen in prurigo lesions (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). These cytokines can also act directly on keratinocytes to impair differentiation and on peripheral sensory neurons (which express IL-4/13 receptors) to lower their activation threshold (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov), thereby linking the immune response to neural hypersensitivity.

Another key pruritogenic cytokine is interleukin-31 (IL-31). IL-31 is a Th2-derived cytokine often dubbed the “itch cytokine” because of its potent induction of pruritus. Lesional skin in chronic prurigo shows a striking overexpression of IL-31 – one study found ~50-fold higher IL31 mRNA levels in prurigo-involved skin vs. healthy skin (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). IL-31 is produced not only by Th2 cells but also by M2 macrophages, mast cells, eosinophils, and keratinocytes (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). In prurigo/LSC lesions, CD3+ T cells and CD68+ macrophages are major sources of IL-31, reflecting a mixed T-cell and innate immune cell infiltrate (pmc.ncbi.nlm.nih.gov). IL-31 exerts its effects via a heterodimeric receptor (IL-31RA/OSMRβ) on target cells including neurons and immune cells. Notably, “IL-31 activates [the] TRPA1 and TRPV1 ion channels on C-fiber neurons, transmitting pruritic signals to the spinal cord”* (pmc.ncbi.nlm.nih.gov). By binding IL-31 receptors on sensory nerves, IL-31 triggers calcium influx through TRP channels (TRPA1, TRPV1), directly causing the itch sensation (pmc.ncbi.nlm.nih.gov). This cytokine–neuron interaction explains why IL-31 blockade has therapeutic benefit: an anti-IL-31 receptor antibody (nemolizumab) significantly reduced itch and improved sleep quality in chronic prurigo clinical trials (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Elevated IL-31 and OSM (oncostatin M) in prurigo lesions correlate with greater itch intensity (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). OSM in the dermis can further amplify type 2 inflammation by recruiting macrophages that secrete IL-31 (pmc.ncbi.nlm.nih.gov). In summary, a Th2-dominant immune milieu – characterized by high IL-4, IL-13, IL-31, and IgE/eosinophil activation (via IL-5) – underlies these disorders (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This leads to chronic allergic inflammation in the skin, analogous to severe eczema. Importantly, Th22 cytokines like IL-22 are also upregulated and contribute to epidermal hyperplasia: “high levels of IL-22 promote keratinocyte hyperplasia and acanthosis, acting synergistically with IL-17 to impair epidermal differentiation in chronic prurigo” (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). IL-22 (often from Th22 or Th17 cells) is known to induce keratinocyte proliferation, explaining the acanthosis (thickening of the epidermis) and hyperkeratosis (scale) in lichenified plaques. Additionally, epidermal keratinocytes release alarmins like thymic stromal lymphopoietin (TSLP) and IL-33 when the barrier is disturbed (pmc.ncbi.nlm.nih.gov). TSLP further skews toward a Th2 response and directly promotes keratinocyte growth, aggravating the hyperplastic, eczematous changes (pmc.ncbi.nlm.nih.gov). In sum, dysregulation of cutaneous immune pathways – especially type 2 immunity – is a core driver of LSC and prurigo. The chronic production of Th2/Th22 cytokines (IL-4, IL-13, IL-31, IL-22, etc.) leads to sustained inflammation, pruritogen release, and tissue remodeling** in the skin.

Neural Sensitization and Peripheral–Central Interactions

LSC and prurigo are often termed “neurodermatitis” due to the critical role of the nervous system. Chronic itch produces profound changes in neural pathways, both in the skin’s peripheral nerves and in the central nervous system (CNS). Patients develop peripheral sensitization – increased excitability of cutaneous itch nerve fibers – as well as central sensitization in the spinal cord and brain (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Repeated stimulation of C-fiber neurons by itch leads to spinal cord plasticity: normally, inhibitory interneurons dampen itch signals, but in chronic pruritus these inhibitory pathways are dysregulated, allowing amplified transmission of itch impulses to the brain (pmc.ncbi.nlm.nih.gov). Functional MRI studies in chronic prurigo patients show augmented activation of brain regions involved in itch and scratch, along with structural changes (e.g. reduced gray matter in areas modulating sensory input) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Clinically, this manifests as a lowered threshold for itch and a heightened urge to scratch (even mild stimuli can trigger severe itch, a phenomenon akin to alloknesis, parallel to allodynia in pain). There is also evidence that chronic scratching causes small-fiber neuropathy or damage in the skin: biopsies of LSC lesions showed decreased intraepidermal nerve fiber density and lower TRPA1 expression in epidermal nerves, indicating that persistent trauma can injure cutaneous nerves (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Paradoxically, while some nerve endings are lost in the epidermis, the dermis of chronic lesions exhibits nerve fiber hyperplasia – an overgrowth and sprouting of regenerating nerves. Prurigo nodularis, in particular, is characterized by prominent dermal neurite proliferation with elevated levels of neuropeptides in the skin. Thin, unmyelinated nerve fibers infiltrate the dermis and even the epidermis of nodules, and they strongly express substance P (Tac1) and calcitonin gene-related peptide (CGRP), both potent itch- and vasodilatory neuropeptides (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). The abundance of these neuropeptides in lesions perpetuates inflammation and itch: substance P can activate mast cells (via the MRGPRX2 receptor) to release additional pruritogens, while CGRP modulates immune cell activity and blood flow. Indeed, one study noted “prominent dermal neuronal hyperplasia, where the neurites express CGRP and substance P” as a hallmark of chronic prurigo lesions (pmc.ncbi.nlm.nih.gov).

At the molecular level, chronic itch involves specialized pruriceptors on sensory neurons. Different subsets of cutaneous C-fibers respond to distinct itch mediators. For example, one subset is activated by histamine (via H1/H4 histamine receptors), another by cytokines like IL-31 and serotonin (expressing IL-31RA and 5-HT3 receptors), and another by certain peptides and proteases (expressing MAS-related G-protein coupled receptors, MRGPRs) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). In chronic prurigo, there is evidence for upregulation of these itch receptors. Notably, MRGPRX2 (a human mast-cell MRGPR) is highly overexpressed in prurigo lesions – over 70% of patients show increased MRGPRX2 mRNA in affected skin (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). MRGPRX2 on mast cells is the key receptor that allows neuropeptides (like substance P and VIP) to directly trigger mast cell degranulation without histamine. This contributes to the non-histaminergic itch component of LSC/prurigo, which often does not respond well to antihistamine therapy (pmc.ncbi.nlm.nih.gov). In fact, it is now recognized that “the itch is non-histaminergic, primarily mediated by protease-activated receptor 2 (PAR2) and type 2 cytokines such as IL-4, IL-13, and IL-31” (pmc.ncbi.nlm.nih.gov). Protease-activated receptor-2 (PAR2) on sensory nerves can be activated by proteases from immune cells or microbes, provoking itch signals. Chronic lesions often harbor increased levels of mast cell tryptase, cathepsin S, and even S. aureus-derived proteases that can cleave and activate PAR2 on nerves (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Additionally, keratinocytes in inflamed skin upregulate TRP channels like TRPV3, a heat-sensitive channel, and these can synergize with PAR2 to amplify itch signaling (pmc.ncbi.nlm.nih.gov). Experiments in atopic dermatitis models show that blocking TRPV3 and PAR2 reduces scratching behavior (pmc.ncbi.nlm.nih.gov), underscoring their role in chronic itch. Finally, interleukin-31’s effect on neuronal TRPA1/TRPV1 channels (noted above) exemplifies how immune mediators directly excite nerves. Overall, chronic LSC and prurigo lead to a state of “neuronal hyper-responsiveness”: due to nerve ending proliferation, increased expression of itch receptors/channels, and loss of inhibitory control, the patient experiences intense itch from minimal stimuli (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This neuroplasticity helps explain why even if the inflammatory infiltrate is treated, patients may still feel phantom itch for some time – their nervous system has been rewired to itch.

Cellular Players and Tissue Context

Multiple cell types participate in the pathogenic circuit of LSC and prurigo. The interface of skin immune cells and cutaneous nerves is especially important. Epidermal keratinocytes are not mere bystanders – they actively contribute to inflammation and itch. When chronically irritated, keratinocytes release pro-inflammatory cytokines (like IL-1, IL-6, TNF-α) and alarmins (TSLP, IL-33) that recruit immune cells. They also can secrete pruritogenic factors in response to stimulation by cytokines; for instance, keratinocytes stimulated by IL-31 have been shown to release additional itch mediators that activate nearby nerve endings (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Langerhans cells and dermal dendritic cells in the skin present antigens and help polarize T-cell responses (e.g. toward Th2), linking barrier disruption to adaptive immunity (pmc.ncbi.nlm.nih.gov). In chronic lesions, biopsies typically show a dermal infiltrate of T lymphocytes, macrophages, mast cells, and often eosinophils, accompanied by epidermal hyperplasia (www.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). T cells in lesions are often of Th2 phenotype (producing IL-4, IL-5, IL-13) or Th22 (producing IL-22), with some Th1 cells as well. Mast cells are increased and in an activated state; interestingly, while mast cells in these lesions produce itch mediators (e.g. tryptase, leukotrienes, histamine), they have limited ability to respond to IL-31 due to low OSMRβ expression (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Instead, macrophages (especially M2-polarized, CD163+ macrophages) appear to be key IL-31 responders in the dermis (pmc.ncbi.nlm.nih.gov). Macrophages not only secrete IL-31 (as noted) but also express the IL-31 receptor complex; they can be triggered by oncostatin M to produce more IL-31, forming an amplifying loop in prurigo lesions (pmc.ncbi.nlm.nih.gov). The majority of cellular infiltrates in chronic prurigo consists of “macrophages, T cells, and mast cells… thought to cause skin inflammation and pruritus by secreting cytokines/chemokines and pruritogens (including IL-31)” (pmc.ncbi.nlm.nih.gov). Eosinophils and basophils are also often present, especially in patients with an atopic background. Eosinophils release toxic granule proteins like eosinophil cationic protein (ECP) and enzymes that can injure tissue and activate nerves; they also produce IL-31 and IL-5, further promoting Th2 loops (pmc.ncbi.nlm.nih.gov). Notably, IL-5 levels (which drive eosinophil growth) are elevated in prurigo nodularis lesions of atopic individuals (pmc.ncbi.nlm.nih.gov), and blood eosinophilia or high total IgE is frequently observed clinically. These findings mirror atopic dermatitis and reinforce that an allergic immune circuit is at work.

The anatomical location of disease is primarily the skin – specifically the epidermis and dermis of areas accessible to scratching (e.g. nape of neck, ankles, extensor limbs). Chronic rubbing leads to localized plaques in LSC (often one or a few sites), whereas chronic prurigo typically presents with multiple nodules on the extremities and trunk. The pathology, however, is not confined to the skin. It involves the peripheral nervous system (cutaneous nerve fibers and dorsal root ganglia) and indeed elements of the central nervous system (spinal cord dorsal horn neurons and brain regions modulating itch) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Thus, LSC and prurigo can be viewed as disorders of the skin–nerve unit: the disease process spans keratinocytes, immune cells, and cutaneous nerves in the skin, plus the upstream neurons in the spinal cord and brain that together mediate chronic pruritus (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). There is even systemic involvement in some patients – for example, elevated serum levels of nerve-derived peptides and neuromodulators have been reported. One study found that B-type (brain) natriuretic peptide (BNP), a neuropeptide hormone, is increased in patients with chronic itch (including prurigo), suggesting central cardiac-neural axis changes (pmc.ncbi.nlm.nih.gov). Additionally, patients often have comorbidities like atopic asthma, allergic rhinitis, or metabolic syndrome, indicating a broader systemic or genetic predisposition to inflammatory and neuroimmune dysregulation (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).

Genetic factors may play a role in susceptibility, although LSC/prurigo are not single-gene disorders. People with an atopic diathesis (e.g. filaggrin gene variants leading to a leaky skin barrier, or high IgE phenotype) are prone to develop lichenification and prurigo when exposed to triggers (www.ncbi.nlm.nih.gov). Recent genetic studies are shedding light on possible causal pathways. For instance, a 2024 Mendelian randomization analysis found that genetically elevated levels of certain circulating cytokines (including T_H2 cytokines) were associated with higher LSC risk (pmc.ncbi.nlm.nih.gov). This suggests the IL-4/IL-13 pathway is not merely reactive but may causally drive disease development. Another study noted that a particular polymorphism in the serotonin transporter gene (SLC6A4) is under-represented in LSC patients, implying that stronger central serotonin signaling might protect against chronic itch (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Epigenetic changes have also been observed: one investigation reported altered LINE-1 DNA methylation patterns in keratinocytes from LSC lesions, hinting at epigenetic regulation in chronic itch skin (pmc.ncbi.nlm.nih.gov). These emerging data reinforce that LSC and prurigo are complex disorders with both environmental (e.g. scratching behavior, allergen exposure, stress) and genetic/immunologic determinants.

Disrupted Biological Processes and Pathways

On a biological process level, LSC and prurigo represent the breakdown of normal skin homeostasis and sensory regulation. Key processes disrupted include:

  • Skin Barrier Function: Chronic scratching mechanically disrupts the stratum corneum barrier. This leads to transepidermal water loss and entry of irritants/microbes, which in turn stimulates keratinocytes to produce pro-inflammatory signals (e.g. TSLP, IL-33) and attract immune cells (pmc.ncbi.nlm.nih.gov). The normal process of keratinocyte differentiation and cornification is impaired; high IL-22 and IL-17 levels cause epidermal hyperplasia and parakeratosis (retention of nuclei in the stratum corneum), as seen histologically (pmc.ncbi.nlm.nih.gov). There is also often dermal edema and fibrosis, indicating aberrant wound-healing responses (excess collagen deposition via activated fibroblasts under IL-4/IL-13 influence) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).

  • Immune Signaling and Cytokine Networks: The normal balance between Th1, Th2, and regulatory signals in skin is skewed toward Th2/Th22. Processes like type 2 immune response (GO:0042092) and IgE-mediated hypersensitivity become overactive. Conversely, any Th1-mediated or regulatory counterbalances are relatively deficient (for example, regulatory T cells or IL-10 signals are not prominently reported in these lesions). The JAK-STAT signaling pathway is chronically engaged due to cytokine-receptor interactions (IL-4R, IL-13R, IL-31R all signal through JAK1/JAK2/STATs) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Hence, the JAK-STAT cascade (GO:0007259) is a key dysregulated pathway; this is therapeutically targetable (JAK inhibitors like upadacitinib have shown efficacy in reducing pruritus) (pmc.ncbi.nlm.nih.gov). Another disrupted pathway is the protease-activated receptor signaling: normally, proteases from keratinocyte desquamation or commensal bacteria are kept in check, but in LSC/prurigo there is excessive PAR-2 activation on nerves and immune cells, fueling itch and inflammation (pmc.ncbi.nlm.nih.gov).

  • Neuroimmune Communication: The crosstalk between nerves and immune cells – mediated by neuropeptides and cytokines – is pathologically amplified. For example, sensory neurons release substance P which should normally be limited, but here it persistently triggers mast cells (via MRGPRX2) to release inflammatory mediators (a feed-forward loop) (pmc.ncbi.nlm.nih.gov). Likewise, immune cytokines such as IL-31 and IL-4 normally might fine-tune itch responses during wound healing, but in chronic lesions they continuously stimulate neurons (via TRP channels and cytokine receptors) causing pathologic itch signaling (pmc.ncbi.nlm.nih.gov). Thus, processes like neuropeptide signaling (GO:0007218) and cytokine-mediated signaling (GO:0019221) are in an aberrant overdrive state. There is also evidence of central neural plasticity; chronic itch involves long-term potentiation-like changes in spinal interneurons and possibly glial cell activation in the cord (similar to chronic pain mechanisms) (pmc.ncbi.nlm.nih.gov). Though not fully elucidated, chronic prurigo likely involves diminished inhibitory neurotransmission in itch pathways and enhanced excitatory transmitter release (e.g. glutamate, BNP) in the dorsal horn.

  • Microbiome and Infection: A dysbiosis of the skin microbiome is another disrupted element. Healthy skin has a diverse flora that educates the immune system and protects against pathogens. In LSC and prurigo lesions, recent 16S sequencing studies (Kim et al, J Invest Dermatol 2023) found reduced bacterial diversity and a predominance of Staphylococcus aureus on lesional skin (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Commensal bacteria like Cutibacterium acnes and Staph. hominis are depleted, which is important because these commensals produce short-chain fatty acids and antimicrobial peptides that normally inhibit S. aureus overgrowth (pmc.ncbi.nlm.nih.gov). With fewer “good” flora, S. aureus thrives and produces exotoxins and proteases (like SplD serine protease) that aggravate inflammation and itch (via PAR2 activation) (pmc.ncbi.nlm.nih.gov). The resultant colonization/infection further damages the skin and perpetuates chronic inflammation. This is analogous to atopic dermatitis, where S. aureus superantigens can drive flares. Indeed, Staphylococcal enterotoxins have been implicated in prurigo nodularis as well (pmc.ncbi.nlm.nih.gov). Thus, the normal biological process of commensal maintenance and pathogen defense is unbalanced in chronic pruritic lesions.

  • Psychoneuroimmunology: Finally, the normally adaptive process by which stress influences immune function becomes pathogenic here. Acute stress typically triggers cortisol release which dampens inflammation, but chronic psychological stress in these patients may instead correlate with lower cortisol and lower neurotrophic support for neurons (pmc.ncbi.nlm.nih.gov). Processes like HPA axis regulation and neurotrophin production (e.g., BDNF, NGF synthesis) are disrupted. Low levels of BDNF and NGF in the central nervous system can reduce the inhibition of itch pathways and have been correlated with higher itch intensity (pmc.ncbi.nlm.nih.gov). In patients with LSC, studies have found elevated scores of anxiety/depression and altered serum neurotrophin levels compared to controls (pmc.ncbi.nlm.nih.gov). Therefore, what is normally a balanced psychosomatic interaction skews toward a vicious cycle: stress exacerbates itch and skin inflammation, which in turn causes more stress.

Disease Progression and Stages

The natural history of LSC and prurigo involves a progression from an initial trigger to chronic established lesions, with potentially distinct phases:

  • Initiation (Trigger Phase): The process often begins with an inciting itch in a localized area. This could be due to an underlying dermatologic condition (e.g. a small eczema patch, an insect bite, contact allergen exposure, or xerosis), a systemic cause of pruritus (such as renal failure, liver disease, or neuropathy), or purely neurogenic itch in predisposed skin (pmc.ncbi.nlm.nih.gov). In many cases there is an atopic predisposition – patients with personal or family history of atopic dermatitis, asthma, or allergic rhinitis – whose skin is more reactive and prone to itch (www.ncbi.nlm.nih.gov). Environmental and psychological triggers (heat, sweat, stress, boredom) can spark the initial bout of itching (pmc.ncbi.nlm.nih.gov). For some, the itch may start during periods of high stress or as a conditioned habit (e.g. scratching for relief or comfort). The lesion at this stage may be mild: just transient erythema or a slightly rough patch from rubbing.

  • Early Lesion Development: If the itch persists and scratching continues, within weeks the affected skin area undergoes epidermal hyperplasia and lichenification. Clinically, one sees a well-demarcated plaque with increased skin markings (in LSC) or the beginnings of a nodular thickening (in prurigo nodularis). Acanthosis (thickening of the epidermis) and dermal fibroblast activation start to become evident histologically (www.ncbi.nlm.nih.gov). There is recruitment of T-cells and macrophages to the skin, attracted by keratinocyte-derived chemokines and mast cell mediators. Patients often report that itching the area provides brief relief followed by worsening (“itch leads to scratch, leads to more itch”), indicating sensitization is underway. The skin may show excoriations or small scabs from intense scratching.

  • Chronic Established Phase: After months, a chronic plaque or nodule is fully established. The skin is markedly lichenified – thick, leathery, often hyperpigmented (especially in skin of color) or sometimes hypopigmented from post-inflammatory changes (pmc.ncbi.nlm.nih.gov). In prurigo nodularis, firm dome-shaped nodules ~1–3 cm form, with a hyperkeratotic or verrucoid surface and often a central crust or ulcer from repeated picking. Multiple lesions can scatter from the primary sites due to koebnerization (new lesions induced by trauma/scratching on previously unaffected skin). Histologically, there is pronounced epidermal hyperplasia with hyperkeratosis, a dense dermal inflammatory infiltrate (lymphocytes, macrophages, mast cells, eosinophils), and neural hyperplasia. Neovascularization (formation of new blood vessels) is also observed in chronic prurigo nodules, likely supporting the metabolic demands of thickened tissue and inflammatory cells (pmc.ncbi.nlm.nih.gov). The dermal fibrosis and enlarged nerves in this phase make lesions particularly recalcitrant. By this stage, the itch sensation can be near-constant and is often described as severe, deep, and prickling, significantly impairing quality of life (patients struggle with insomnia and distress due to unrelenting itch). Notably, as the disease becomes chronic, secondary neural plastic changes make the itch self-sustaining – even if an underlying trigger (like a healed rash or resolved neuropathy) is removed, the lesion of LSC or prurigo may continue to itch on its own. This is why breaking the itch-scratch cycle early is critical.

  • Potential Resolution/Remission: With proper treatment (e.g. potent topical steroids, calcineurin inhibitors, anti-IL-4R or anti-IL-31 biologics, neuro-modulators like gabapentin), lesions can enter a healing phase. The skin gradually loses the pruritic drive, allowing patients to refrain from scratching. Over time, the thick plaques or nodules can flatten, though often post-inflammatory hyperpigmentation or scarring remains. In some patients, especially with prurigo nodularis, lesions may persist for years or chronically recur even with therapy, reflecting how entrenched the neuroimmune circuits can become. There is no formal “stage 4” organ damage as in systemic diseases, but chronic prurigo is now recognized as a disease in its own right rather than just a symptom (pmc.ncbi.nlm.nih.gov).

It is important to note that LSC and chronic prurigo do not “progress” to systemic illness or death – their morbidity lies in chronic discomfort and skin changes. However, they can be persistent and relapsing. Patients often have a background of chronic conditions (atopy, underlying diseases) that need concurrent management. In a subset, addressing an underlying cause (e.g. treating hep C in prurigo, or relieving a pinched nerve) can halt new lesion formation, but existing lesions still need direct dermatologic and behavioral therapy to resolve.

Clinical Phenotypes and Mechanistic Correlates

The phenotypic manifestations of LSC and prurigo are the tangible outcomes of the above pathophysiological processes. Chronic pruritus (HP:0000989) is the cardinal symptom – patients experience relentless itching in specific areas of skin. This itch is often worse at night or during stress, corresponding to times of lowered distraction or heightened cortisol fluctuations (tying into circadian and stress hormone influences). The intensity of itch correlates with the local cytokine and neuropeptide milieu; for example, higher IL-31 and IL-31RA levels in lesions are closely related to worse pruritus scores (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). The visible skin changes result from repeated scratching trauma and inflammatory remodeling: lichenification (HP:0011353) – thick, accentuated skin markings with a corrugated appearance – is characteristic of LSC, especially on the neck, scalp, extensor forearms, ankles, or genital areas (common locations patients can chronically scratch) (pmc.ncbi.nlm.nih.gov). The plaques are typically single or few in number, with well-demarcated borders, and can have hyperpigmented or violaceous coloration in long-standing cases (pmc.ncbi.nlm.nih.gov). In prurigo nodularis, the phenotype is multiple pruritic nodules (HP:0010674), often symmetrically distributed on the arms and legs. These nodules are firm and dome-shaped with a scaly surface. They arise from the convergence of intense inflammation, fibrosis, and apoptosis-resistant keratinocyte hyperplasia – essentially, the chronic lesion “organizes” into a tumor-like nodule under the influence of persistent Th2 cytokines and growth factors (like TGF-β stimulating fibroblasts). The presence of excoriations (HP:0000988), crusts, and occasionally pustules (if secondarily infected) on these lesions is common, due to the patient’s scratching and picking.

Patients often exhibit post-inflammatory hyperpigmentation (HP:0005309) or lichen simplex pigmentosus, especially in darker skin phototypes, as a consequence of chronic inflammation and melanocyte stimulation in scratched areas (www.ncbi.nlm.nih.gov). Less often, repeated scratching can cause hypopigmented patches or even scarring. Another phenotype aspect is the psychological and sleep disturbance: chronic prurigo is associated with insomnia, depression, and anxiety (these could be considered comorbid phenotypes or consequences). Although not skin lesions per se, symptoms like sleep impairment (HP:0002360) and emotional distress are directly tied to the pathophysiology – the nocturnal peak of IL-31 and other pruritogens can awaken patients with intense nocturnal itch, and chronic cytokine elevation (like TNF-α and IL-6) is known to disrupt sleep patterns (pmc.ncbi.nlm.nih.gov). Likewise, the stress from itching can feed back to worsen neuroimmune balance, as described.

Histologically, the phenotype corresponds to specific microscopic features: LSC and prurigo lesions show hyperkeratosis, acanthosis, and a lichenoid dermal infiltrate with fibrosis (www.ncbi.nlm.nih.gov). This correlates with the clinical thickness and firmness of lesions. Eosinophils in the infiltrate might correspond to any overlying excoriations or urticaria-like components. Mast cell prominence can sometimes be seen as dermal urtication. The neural hypertrophy is not visible clinically but correlates with heightened tenderness or dysesthesia some patients report when lesions are touched (due to excessive nerve fibers).

It’s also notable that these conditions have links to other phenotypic “syndromes.” For example, prurigo nodularis often coexists with atopic dermatitis (some patients fulfill criteria for both, hinting at a systemic atopic phenotype). LSC on the scalp or occiput can resemble pickers nodule or even be misdiagnosed as psoriasis initially; however, the history of habitual scratching and absence of robust psoriatic plaques distinguishes it. Chronic scratching in the nuchal area can lead to an “LSC mullet” – a patch of hair loss and thickened skin known as neurodermatitis of the scalp. In genital areas, chronic scratching results in lichenified vulvar or scrotal plaques that clinically overlap with lichen sclerosus or squamous hyperplasia (necessitating biopsy if atypical, to rule out dysplasia) (pmc.ncbi.nlm.nih.gov). These examples show how the phenotype can vary by location but is unified by the underlying mechanism of chronic itch and trauma.

In summary, the clinical phenotypes of LSC and prurigo (itchy lichenified plaques or nodules with chronic eczema-like changes) are direct reflections of their pathophysiology. The itch-scratch cycle produces the skin changes (lichenification, nodularity, pigment alteration), while the molecular drivers – Th2 cytokines, neural growth factors, and pruritogens – correlate with disease severity and chronicity. Each clinical feature, from thickened skin to intense itch, can be mapped back to one or more underlying mechanisms: e.g. lichenified, hyperkeratotic skin is due to chronic keratinocyte stimulation by IL-22 and trauma; fibrotic nodularity is due to IL-4/IL-13-induced collagen deposition; severe itch is due to IL-31, PAR2 activation, and neural sensitization; distribution of lesions reflects accessible scratch areas and possibly dermatomal neural sensitization in some cases. Understanding these correlations has practical implications – for instance, the success of IL-4/IL-13 blockade (dupilumab) in improving prurigo nodularis validates the role of Th2 pathways (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov), and ongoing trials of IL-31 inhibitors and JAK inhibitors are founded on the molecular pathways outlined above (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Thus, the phenotypes are not only endpoints but also guides to the active pathogenic pathways, enabling clinicians to target therapy (e.g. using nemolizumab for IL-31-driven itch, or gabapentinoids for neural hyperexcitability) in this complex neuroimmune skin disorder.

References:

  1. Charifa A et al. (2023). Lichen Simplex Chronicus. StatPearls Publishing. PMID: NBK499991 (Pathophysiology: itch–scratch cycle and neuroimmune linkage) (www.ncbi.nlm.nih.gov) (www.ncbi.nlm.nih.gov).
  2. Liao V et al. (2024). Prurigo nodularis: new insights into pathogenesis and novel therapeutics. Br J Dermatol. 190(6):798–810. PMID: 38345154 (Th2/IL-4/IL-13 pathways and fibrotic remodeling) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).
  3. Ständer S et al. (2022). Chronic nodular prurigo/Prurigo nodularis – consensus terminologies. J Eur Acad Dermatol Venereol. 36(8):1319–1324. PMID: 35384179 (definition of chronic prurigo as distinct neuroimmune entity) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).
  4. Moshkovich M et al. (2025). Lichen Simplex Chronicus: Clinical Perspectives and Emerging Therapeutic Strategies. Am J Clin Dermatol. 26(6):895–903. PMID: 40855389 (neuroimmune pathophysiology of LSC; IL-31 and TRP channel role) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).
  5. Abdat R et al. (2022). Mechanisms of Itch in Atopic Dermatitis and Prurigo Nodularis. Curr Dermatol Rep. 11:159–169. PMID: 35190715 (IL-31, nerve growth factors, and chronic itch mediators) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).
  6. Kim HS et al. (2023). Characterization of a perturbed skin microbiome in prurigo nodularis and lichen simplex chronicus. J Invest Dermatol. 143(8):2082–2085.e5. PMID: 36889588 (lesional dysbiosis with Staph. aureus dominance in chronic pruritic dermatoses) (pmc.ncbi.nlm.nih.gov).
  7. Altunay IK et al. (2021). More than a skin disease: stress, depression, anxiety levels, and serum neurotrophins in lichen simplex chronicus. An Bras Dermatol. 96(6):700–705. PMID: 34777865 (psychological stress, low BDNF/NGF levels, and itch severity in LSC) (pmc.ncbi.nlm.nih.gov).